Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
Cytokinetics reported strong initial sales of MYQORZO following its U.S. launch in late January 2026 with over 275 healthcare providers prescribing to approximately 680 patients, generating $4.8 million net revenue in Q1. The company announced positive top-line results from the ACACIA-HCM Phase 3 trial, showing efficacy in non-obstructive hypertrop…